Ori Biotech Bags €88M Investment to Automate Cell Therapy Manufacture
The UK company Ori Biotech has raised €88M ($100M) in Series B cash to ease…
18/01/2022 - 4 minutes
News and Trends
Two Gene Therapy Players Launch IPOs on Stormy Stock Market
After a drought of more than a year, the European gene therapy sector saw initial…
21/01/2022 - 4 minutes
News and Trends
Engitix Builds Liver Disease Pipeline with Series A and Drug Collaboration
With the close of its Series A round at €48M ($54M), the tissue models company…
19/01/2022 - 3 minutes
In Depth
Glycans Hit the Sweet Spot in Diagnostics
The surface of our cells are covered in sugar molecules called glycans. The field of…
- 5 minutes
What's New
MoreBiomining: Turning Waste into Gold with Microbes
High-value metals make the modern world go round, but the way we extract and dispose…
18/01/2022 - 7 minutes
Labiotech.eu Is Being Acquired by Inova
We’ve got some amazing news we’re dying to tell you about, and now we can…
18/01/2022 - 2 minutes
Swiss Startup Signs on with Novo Nordisk to Discover Obesity Treatments
The Swiss startup EraCal Therapeutics has signed a research partnership with the Danish pharmaceutical giant…
17/01/2022 - 3 minutes
Europe Trailed US Despite Record Gene and Cell Therapy Funding in 2021
Cell and gene therapy developers globally raised an all-time annual record in 2021. However, European…
14/01/2022 - 6 minutes
Biotech Startup Incubators Prepare to Cash in on Record VC Funding
Venture capital funding broke records in the biotech industry in 2021. Leading startup incubators from…
13/01/2022 - 7 minutes
From Our Partners
View More
Sponsored
by Cytiva
How to Make Cell Culture Expansion Easy
Sponsored
by Precision for Medicine
How a Berlin-Based Biotech Pushes the Limits of Immune Cell Monitoring
Sponsored
by Link Medical
Why Biostatisticians are Essential for Successful Clinical Trial Management
Sponsored
by Charles River Laboratories
Using Cell Microarrays to Detect Off-Target Effects in Drug Development
Download our industry reports
View all our reports
